HOME >> MEDICINE >> NEWS
Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease

FREMONT, Calif., May 18, 1999 -- Abgenix, Inc. (Nasdaq: ABGX) reported today additional results of a Phase II clinical trial of ABX-CBL in graft versus host disease ("GVHD"). ABX-CBL is a proprietary in-licensed mouse antibody that binds to the CBL antigen. The CBL antigen is upregulated on activated immune cells, including T cells, B cells and natural killer cells. The completed trial involved patients in four dose cohorts with severe GVHD, an often fatal side effect of bone marrow transplants ("BMT"). Among patients in the three higher dose cohorts, 56% (10 of 18) survived at least 100 days from the start of treatment with ABX-CBL. This compared favorably to a 22% (2 of 9) survival rate in the low dose cohort. Robert Rivkin, M.D. of the Rocky Mountain Cancer Centers in Denver, Colorado, presented the details of the clinical trial today at the 1999 Annual Meeting of the American Society of Clinical Oncology.

"We believe the survival data reported today strengthens the preliminary safety and response rate data reported earlier," stated R. Scott Greer, president and chief executive officer of Abgenix. "We plan to initiate a pivotal Phase III clinical trial for ABX-CBL as soon as feasible after we have approval from the FDA to proceed."

In March, at the International Bone Marrow Transplant Registry ("IBMTR") meeting, it was reported that, among patients in the three higher dose cohorts, 73% (11 of 15) had a two grade or better improvement in the IBMTR GVHD Severity Scale. This compared favorably to a 25% (2 of 8) response rate in the low dose cohort.

GHVD is a life threatening complication that frequently occurs following an allogeneic BMT. BMTs are used in the treatment of patients with end stage leukemia, certain other serious cancers and immune system disorders. An allogeneic BMT procedure involves transferring marrow, the graft, from a healthy person into an immunosuppressed patient, the host. The transplant is intended to restore nor
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
18-May-1999


Page: 1 2

Related medicine news :

1. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
2. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
3. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
4. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
5. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
6. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
7. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
8. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
9. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
10. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports
11. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/18/2019)... SCOTCH PLAINS, N.J. (PRWEB) , ... September 18, ... ... Michael L. Scagnelli, DMD for the fourth consecutive year. Dr. Scagnelli specializes in ... Matawan-based practice was established in the 1940’s and has been delivering quality dental ...
(Date:9/17/2019)... ... 17, 2019 , ... Six Consulting Inc. (SIX) recently announced ... – specifically golden retrievers - through innovative cancer prevention medicine. A national survey ... out of five retrievers in the United States will die from a particular ...
(Date:9/17/2019)... ... ... Lubin Austermuehle, P.C. will be one of the sponsors of GRIN2B ... Found Kitchen and Social House in Evanston on Monday, October 7 from 6 p.m. ... rare condition that results from changes to the GRIN2B gene. The GRIN2B gene is ...
(Date:9/17/2019)... LYNDHURST, N.J. (PRWEB) , ... September 17, 2019 ... ... in a wide array of services, welcomes Dr. Yevgeniya (Jenny) Gartshteyn to their ... University Medical Center, where she previously held the Clinical Appointment of Assistant Professor ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful source of ... disease as he hopes to prevent anyone from having it and to help those ... Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to experience another ...
Breaking Medicine News(10 mins):
(Date:9/17/2019)... ... September 17, 2019 , ... Today, in ... reproductive justice, contraception and consent with student and faculty from The City University ... which included Francisco Ramirez, MPH; Elise Schuster, MPH; Raffaele M. Bernardo, DO, FACP, ...
(Date:9/17/2019)... ... ... Embr Labs , the breakthrough thermal technology company and creator of ... Partners, with participation from Safar Partners, Joyance Partners , Bose Ventures ... footprint in wellness and digital therapeutics, accelerate development for the next generation of its ...
(Date:9/17/2019)... ... September 17, 2019 , ... Gustavo Grodnitzky, PhD will join the faculty of ... as holistic mind/body medicine for physicians and other health care professionals. Entitled The ... at the Cranwell Resort and Spa in Lenox, Massachusetts, is accredited by the Albany ...
Breaking Medicine Technology:
Cached News: